Skip to main content
PACIFIC EDGE LIMITED logo

PACIFIC EDGE LIMITED — Investor Relations & Filings

Ticker · PEB ISIN · NZPEBE0002S1 LEI · 9845007EDCF068FFEA12 ASX Professional, scientific and technical activities
Open in API
Filings indexed 749 across all filing types
Latest filing 2019-12-10 Regulatory Filings
Country NZ New Zealand
Listing ASX PEB

About PACIFIC EDGE LIMITED

https://www.pacificedgedx.com/

Pacific Edge Limited is a cancer diagnostics company specializing in the development and commercialization of non-invasive molecular diagnostic tests. The company's primary product suite, Cxbladder, utilizes advanced mRNA biomarker technology to detect and monitor bladder cancer from urine samples. These genomic tests are designed to assist clinicians in the evaluation of patients presenting with hematuria and in the ongoing surveillance of patients previously diagnosed with the disease. By providing high sensitivity and negative predictive value, the Cxbladder suite helps to accurately rule out urothelial carcinoma, potentially reducing the requirement for invasive clinical procedures such as cystoscopy. The company focuses on integrating its diagnostic tools into standard clinical pathways to improve patient outcomes and healthcare efficiency.

Recent filings

Filing Released Lang Actions
D&O Ongoing Disclosure – Chris Gallaher
Regulatory Filings
2019-12-10 English
D&O Ongoing Disclosures – Multiple
Regulatory Filings
2019-12-09 English
Amended: D&O Ongoing Disclosure – John Duncan
Regulatory Filings
2019-12-05 English
Important Reminder: PEB Rights Offer closing soon
Capital/Financing Update Classification · 95% confidence The document is a letter to shareholders reminding them about the closing date of a rights offer, which is a capital raising activity. It explains the rights offer terms, how shareholders can participate, and provides instructions for acceptance. There is no financial data, no report attached or referenced as published, and the document is relatively short (3291 characters). This is an announcement related to a capital raising event, specifically a rights issue, which fits the Capital/Financing Update category. It is not a full financial report or regulatory filing, nor is it a proxy or voting announcement. Therefore, the correct classification is Capital/Financing Update (CAP).
2019-12-05 English
D&O Ongoing Disclosure – John Duncan
Regulatory Filings
2019-12-04 English
PEB Rights Issue Documents
Capital/Financing Update Classification · 95% confidence The document is an offer to acquire new ordinary shares through a fully underwritten pro-rata renounceable rights offer. It discusses capital raising, shareholder options regarding rights, and subscription deadlines. There is no financial report, earnings data, or management discussion of results. The content focuses on financing activities and capital structure changes. The document length is short (2614 characters) and it is an offer document related to capital raising, not a report or announcement of a report publication. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2019-11-27 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.